COVID-19 pandemic The Japanese Health Ministry panel commitee approve single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately ill COVID-19 patients. Japan panel approves second drug for mildly ill COVID-19 patients © The Japan Times Sources: The Japan Times